Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegargiminase - Polaris Pharmaceuticals

Drug Profile

Pegargiminase - Polaris Pharmaceuticals

Alternative Names: ADI-PEG; ADI-PEG 20; ADI-SS PEG; Arginine deiminase pegylated; Arginine deiminase-PEG; Hepacid; Melanocid; PEG arginine deiminase; Pegylated arginine deiminase - Polaris Group

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer Barts and The London School of Medicine and Dentistry; Memorial Sloan-Kettering Cancer Center; Polaris Pharmaceuticals; University of Miami; Washington University School of Medicine
  • Class Antineoplastics; Hepatoprotectants; Hydrolases; Polyethylene glycols; Proteins; Radiosensitisers
  • Mechanism of Action Arginine deiminase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant-mesothelioma; Liver cancer; Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Malignant-mesothelioma
  • Phase III Leiomyosarcoma; Liver cancer; Soft tissue sarcoma
  • Phase II/III Glioblastoma
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Non-alcoholic steatohepatitis; Non-Hodgkin's lymphoma; Small cell lung cancer
  • No development reported Bladder cancer; Breast cancer; Cancer; Gastrointestinal cancer; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Uveal melanoma; Viral infections

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Taiwan (IM)
  • 09 Apr 2024 Pharmacodynamics data from a preclinical trial in Uveal melanoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 05 Apr 2024 Polaris Pharmaceuticals plans a clinical trial for Uveal melanoma (Combination therapy) in December 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top